| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Lise L Gluud | Q52353956 |
| P2093 | author name string | Flemming Bendtsen | |
| Lise Hobolth | |||
| Marsha Y Morgan | |||
| Rebecca Jeyaraj | |||
| Antony P Zacharias | |||
| P2860 | cites work | Carvedilol or propranolol in portal hypertension? A randomized comparison | Q83607191 |
| The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5 | Q84997585 | ||
| Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT | Q88324922 | ||
| Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions | Q24193207 | ||
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis | Q27013775 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| Clinical role of non-invasive assessment of portal hypertension | Q28468382 | ||
| A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints | Q29614902 | ||
| Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic | Q31043168 | ||
| Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database | Q31087679 | ||
| Imputation methods for missing outcome data in meta-analysis of clinical trials | Q31159481 | ||
| Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches | Q33201947 | ||
| Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review | Q33263463 | ||
| Pharmacological treatment of portal hypertension: an evidence-based approach | Q33822133 | ||
| Prediction of variceal hemorrhage by esophageal endoscopy | Q34274411 | ||
| Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. | Q34469981 | ||
| How to formulate research recommendations | Q35082894 | ||
| Prevention of variceal rebleeding | Q35089529 | ||
| Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions | Q35136411 | ||
| Evaluation of carvedilol for the treatment of portal hypertension | Q35637082 | ||
| The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis | Q35707623 | ||
| Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis | Q36008972 | ||
| Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients | Q36134590 | ||
| Molecular and structural basis of portal hypertension | Q36680434 | ||
| Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. | Q36903148 | ||
| A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage | Q37171323 | ||
| The role of carvedilol in the management of portal hypertension | Q37679680 | ||
| Hepatic venous pressure gradient: clinical use in chronic liver disease | Q37711328 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies | Q38044510 | ||
| Natural history of cirrhosis. | Q38073661 | ||
| Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis | Q38220070 | ||
| Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments | Q38446357 | ||
| Prevention and treatment of variceal haemorrhage in 2017. | Q39067320 | ||
| A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. | Q39440287 | ||
| Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production | Q39544003 | ||
| Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis | Q42551434 | ||
| Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis? | Q43234003 | ||
| Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis | Q43545317 | ||
| Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage | Q43560935 | ||
| Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers | Q43770467 | ||
| Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. | Q43904253 | ||
| Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics | Q43967445 | ||
| Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis | Q44226729 | ||
| Incidence and natural history of small esophageal varices in cirrhotic patients | Q44370094 | ||
| Improved patient survival after acute variceal bleeding: a multicenter, cohort study | Q44371369 | ||
| Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. | Q44458153 | ||
| Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators | Q44562447 | ||
| Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis | Q45077758 | ||
| How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. | Q46869926 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials | Q47192223 | ||
| Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding | Q47320079 | ||
| Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. | Q48219904 | ||
| Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. | Q54100725 | ||
| Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. | Q54331027 | ||
| Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. | Q54512131 | ||
| Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol | Q57168135 | ||
| Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension | Q58034591 | ||
| Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis | Q62616250 | ||
| Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis | Q62616324 | ||
| Industry sponsorship and research outcome: systematic review with meta-analysis | Q64122695 | ||
| Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study | Q68097576 | ||
| Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices -- a prospective controlled randomized trial | Q70213528 | ||
| The general rules for recording endoscopic findings on esophageal varices | Q71190324 | ||
| Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients | Q72468713 | ||
| Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension | Q73338810 | ||
| Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes | Q79354256 | ||
| Improved survival after variceal bleeding in patients with cirrhosis over the past two decades | Q80531093 | ||
| Cost of treatment of oesophageal variceal bleeding in patients with cirrhosis in France: results of a French survey | Q80599243 | ||
| Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis | Q82853308 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carvedilol | Q412534 |
| varicose veins | Q201180 | ||
| P304 | page(s) | CD011510 | |
| P577 | publication date | 2018-10-29 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices | |
| P478 | volume | 10 |
Search more.